Lexaria's Robust Patent Portfolio Continues to Grow [Yahoo! Finance]
Lexaria Bioscience Corp. (LEXX)
Company Research
Source: Yahoo! Finance
KELOWNA, BC / ACCESS Newswire / March 26, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this update on additional new intellectual property ("IP") granted to the Company as a result of its ongoing research and development ("R&D") programs. This new IP is recognized with the awarding of 5 new patents as detailed below. "Lexaria is very proud of its internal team for their ingenuity and dedication to pushing scientific boundaries and also to having these achievements recognized by patent offices around the world," said Richard Christopher, CEO of Lexaria. "In particular, given the international race within the GLP-1 industry, our new patents related to diabetes treatments utilizing our proprietary technology in conjunction with already-approved GLP-1 drugs is a notable achievement." In Lexaria's patent Family #21, Compositions and Methods for Treating Hypertension , we have received 2
Show less
Read more
Impact Snapshot
Event Time:
LEXX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEXX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEXX alerts
High impacting Lexaria Bioscience Corp. news events
Weekly update
A roundup of the hottest topics
LEXX
News
- Lexaria Bioscience: Oral Drug Delivery Technology Targets Next-Gen Weight Loss Market [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Lexaria Bioscience: Improving Oral Weight-Loss Drug Tolerability [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke PointGlobeNewswire
LEXX
Sec Filings
- 3/18/26 - Form 4
- 2/6/26 - Form 8-K
- 1/28/26 - Form 8-K
- LEXX's page on the SEC website